Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme.

Online article in the Managing Intellectual Property website.

In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s pipeline and IP estate, ultimately driving the value of de-risked assets several fold in the last decade. For internally generated IP, pharma strategy has also relied on so-called carpet bombing patent claim practices, targeting indications beyond those which have been proven scientifically in an effort to ensure better protection of the main discovery, and of course, lay claim to potential future opportunities.

Read More…